

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BioDlink International Company Limited**

**東曜藥業股份有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1875)**

## **RETIREMENT OF EXISTING AUDITOR AND PROPOSED APPOINTMENT OF NEW AUDITOR**

### **RETIREMENT OF AUDITOR**

The board of directors (the “**Board**”) of BioDlink International Company Limited (the “**Company**”) announces that PricewaterhouseCoopers (“**PwC**”) will retire as auditor of the Company upon expiration of its current term of office at the conclusion of the forthcoming annual general meeting (the “**AGM**”).

PwC has provided a confirmation that there is no circumstance connected with their retirement which they consider should be brought to the attention of the Company’s members and creditors. The Board is not aware of any other matter regarding the retirement of auditor that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”, and each a “**Shareholder**”).

The Board believes that the retirement of PwC will not have any significant impact on the annual audit and the release of annual results of the Group for the financial year ending 31 December 2026.

### **PROPOSED APPOINTMENT OF NEW AUDITOR**

The Board, with recommendation from the Audit and Connected Transactions Review Committee of the Board (the “**Audit and Connected Transactions Review Committee**”), has resolved to propose the appointment of Deloitte Touche Tohmatsu (“**Deloitte**”) as the new auditor of the Company (the “**Proposed Appointment**”) after the retirement of PwC and to hold office until the conclusion of the next AGM, subject to the approval by the Shareholders at the forthcoming AGM.

## **REASONS FOR THE CHANGE**

PwC has been serving as the auditor of the Company since the listing of the Company in 2019. Having regard to the length of PwC's tenure, the Board considers that rotation of auditor after an appropriate period of time is a good corporate governance practice. The Board has decided to change the auditor, as it considers that the change of auditors is in the best interests of the Company and the Shareholders as a whole and believes that aligning the auditor firm with that of its controlling shareholder will streamline the audit process and enhance communication efficiency.

It is understood that WuXi XDC Cayman Inc. (whose shares are listed on The Stock Exchange of Hong Kong Limited ("**Stock Exchange**") under stock code 2268) ("**WuXi XDC**"), the controlling shareholder of the Company, has also proposed to appoint Deloitte as the auditor for the year ending 31 December 2026. If the same audit firm as that appointed by WuXi XDC is engaged to provide services, it is believed that there will be greater advantages in the future in terms of facilitating communication mechanisms, improving audit efficiency and controlling costs and expenses.

## **ASSESSMENT BY THE AUDIT AND CONNECTED TRANSACTIONS REVIEW COMMITTEE**

The Audit and Connected Transactions Review Committee has considered a number of factors in assessing the proposed appointment of Deloitte as the auditor of the Company in accordance with its terms of reference, including but not limited to (i) Deloitte's audit proposal and audit fee; (ii) its experience, industry knowledge and technical competence in providing audit work for companies listed on the Stock Exchange; (iii) its independence from the Group and objectivity; (iv) its market reputation; (v) its resources and capabilities; and (vi) the relevant guidance issued by the Hong Kong Accounting and Financial Reporting Council.

The estimated audit fee for the year ending 2026 is approximately RMB2.7 million (comprising (i) approximately RMB2.2 million for audit services and (ii) approximately RMB500,000 for non-audit services), which is determined with reference to the proposed audit scope, the Company's current size, complexity and risk profile and the expected level of effort and timeline of the audit, and on the assumption that there will be no material change to the Company's business.

The Company's auditor also allocates optimised resource and manpower to ensure that the audit will be performed to a high standard and in accordance with all applicable auditing standards. The Audit and Connected Transactions Review Committee noted that the proposed audit fee is determined after arm's length negotiations.

The Board and the Audit and Connected Transactions Review Committee have reviewed the qualifications, competence and experience of Deloitte and considered that Deloitte (i) meets the regulatory requirements, and (ii) is eligible and suitable to act as the auditor of the Company. In light of the above, the Board considers that the change of auditors is in the best interests of the Company and the Shareholders as a whole.

A circular containing, among other things, details of the proposed change of auditors together with the notice convening the forthcoming AGM will be despatched to the Shareholders in due course.

By order of the Board  
**BioDlink International Company Limited**  
**Dr. Jincal LI**  
*Chairperson*

Hong Kong, 4 June 2026

*As at the date of this announcement, the executive Director is Dr. Jincal Li; the non-executive Director is Mr. Xiaojie Xi; and the independent non-executive Directors are Mr. Xin Fan, Dr. Ulf Grawunder and Dr. Chaohong Hu.*